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Abstract   
Background: Novel therapeutic approaches are required to treat ovarian cancer and 
dependency on glycolysis may provide new targets for treatment. This study sought to 
investigate the variation of expression of molecular components (GLUT1, HKII, PKM2, LDHA) 
of the glycolytic pathway in ovarian cancers and the effectiveness of targeting this pathway 
in ovarian cancer cell lines with inhibitors. 
Methods: Expression of GLUT1, HKII, PKM2, LDHA were analysed by quantitative 
immunofluorescence in a tissue microarray (TMA) analysis of 380 ovarian cancers and 
associations with clinicopathological features were sought. The effect of glycolysis pathway 
inhibitors on the growth of a panel of ovarian cancer cell lines was assessed by use of the SRB 
proliferation assay. Combination studies were undertaken combining these inhibitors with 
cytotoxic agents. 
Results: Mean expression levels of GLUT1 and HKII were higher in high grade serous ovarian 
cancer (HGSOC), the most frequently occurring subtype, than in non-HGSOC. GLUT1 
expression was also significantly higher in advanced stage (III/IV) ovarian cancer than early 
stage (I/II) disease. Growth dependency of ovarian cancer cells on glucose was demonstrated 
in a panel of ovarian cancer cell lines. Inhibitors of the glycolytic pathway (STF31, IOM-1190, 
3PO and oxamic acid) attenuated cell proliferation in platinum-sensitive and platinum-
resistant HGSOC cell line models in a concentration dependent manner. In combination with 
either cisplatin or paclitaxel, 3PO (a novel PFKFB3 inhibitor) enhanced the cytotoxic effect in 
both platinum sensitive and platinum resistant ovarian cancer cells. Furthermore, synergy 
was identified between STF31 (a novel GLUT1 inhibitor) or oxamic acid (an LDH inhibitor) 
when combined with metformin, an inhibitor of oxidative phosphorylation, resulting in 
marked inhibition of ovarian cancer cell growth.  
Conclusions:  The findings of this study provide further support for targeting the glycolytic 
pathway in ovarian cancer and several useful combinations were identified. 
 
Keywords: ovarian cancer, glycolytic pathway, inhibitors, combination strategies, cisplatin, 
metformin 
Background 
Ovarian cancer is the 7th most common female cancer worldwide with an estimated 239,000 
new diagnoses worldwide each year [1]. Standard treatment of ovarian cancer consists of 
debulking surgery followed by systemic platinum and taxane-based chemotherapy. Even 
though platinum-based chemotherapy has a high response rate, it is estimated that 
approximately 70% of patients will relapse with resistant disease and new treatments are 
required [2]. High-grade serous ovarian cancer (HGSOC) accounts for approximately 70% of 
epithelial ovarian cancers while non-HGSOC which includes endometrioid, clear cell, 
mucinous and low-grade serous ovarian cancer, among others, comprise important 
subgroups [2]. 
Many cancer cells rely on glycolysis as their primary source of energy regardless of oxygen 
availability; the persistence of glycolysis in cancer cells even under aerobic conditions is 
termed aerobic glycolysis or the Warburg effect. This metabolic alteration in tumours has 
been extensively demonstrated in a wide variety of cancers and considered a ‘hallmark’ of 
advanced malignancy [3-5]. It has been estimated that many tumour cells under aerobic 
conditions produce up to 60% of their ATP requirement through glycolysis [6, 7]. This 
‘metabolic reprogramming’ is an adaptation to meet the requirements of highly proliferative 
malignant tissues, providing the precursors needed to support biosynthesis [8, 9]. 
Furthermore, the metabolic alteration of cancer cells can provide them with a selective 
advantage for survival and growth in low oxygen tumour microenvironments. As tumours 
grow and expand away from a functional blood supply, glycolysis is an evolutionary 
adaptation of cells to survive and thrive in a hypoxic environment [3, 7, 10]. This reliance on 
glycolysis provides a possible therapeutic opportunity and the enzymes comprising the 
glycolytic pathway may be potential targets for cancer treatment [6, 10-17]. Several glycolytic 
inhibitors have emerged as exhibiting promising anticancer activity both in vitro and in vivo 
and a number have reached clinical trials [10-13, 16].  
Glucose transporter 1 (GLUT1) is the first component of the glycolysis pathway, transporting 
glucose into the cell, and is up-regulated in many tumour types. High expression has been 
associated with poor clinical outcome and adverse prognosis [18-20]. STF31 [4-[[[[4-(1, 1-
Dimethylethyl)phenyl]sulfonyl]amino]methyl]-N-3-pyridinylbenzamide] is a pyridyl-anilino-
thiazole that impairs glycolytic metabolism and binds to the GLUT1 transporter [21]. Based 
on molecular modelling, STF31 was predicted to interact directly with the central pore of the 
transporter and was shown to inhibit glucose uptake and induce necrotic cell death selectively 
in glycolytic cancer cells. In vivo efficacy of the compound was also demonstrated [21]. IOM-
1190 is a GLUT1 inhibitor that suppresses 2-deoxy-D-glucose (2-DG) uptake and lactate 
production in A549 lung cancer cells resulting in rapid apoptotic cell death. High affinity for 
GLUT1 binding of the radiolabelled compound has also been documented [22]. 
Hexokinase catalyses the first rate-controlling irreversible reaction of the glycolytic pathway; 
phosphorylating glucose to glucose-6-phosphate coupled with ATP de-phosphorylation. The 
mitochondrial-bound isoform HKII is considered to play a pivotal role in carcinogenesis and is 
overexpressed in many tumours [23, 24]. 
6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase (3PFKFB3), which converts fructose-6-
phosphate to fructose-2,6-bisP (F2,6BP), is downstream of HKII. PFKFB3 overexpression has 
been documented in several tumour types including ovarian cancers [25]. In 2008, Clem et al 
identified a competitive inhibitor of PFKFB3, 3PO, using computational modelling and virtual 
database in silico screening. 3PO [3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one] is a novel 
small molecule, dipyridinyl-propenone based compound that reduced intracellular F2,6BP 
levels, glucose uptake and lactate production followed by induction of G2-M phase cell cycle 
arrest. 3PO treatment suppressed tumour growth in vivo in mice bearing leukaemia, lung and 
breast adenocarcinoma xenografts [26].  
Further downstream is the M2 isozyme of pyruvate kinase (PKM2) which catalyses the 
irreversible conversion of phosphoenolpyruvate (PEP) to pyruvate coupled with ADP 
phosphorylation and is found overexpressed in various tumour types and plays a pivotal role 
in carcinogenesis [27, 28].  
Lactate dehydrogenase A (LDHA) is the enzyme catalysing the reduction of pyruvate in the 
final step of the glycolytic pathway. LDHA upregulation has been reported in ovarian cancers 
when compared to normal tissues [29]. LDHA overexpression is considered to have a crucial 
role in tumorigenesis and is often associated with poor clinical outcome and resistance to 
therapy [30-32]. Oxamic acid is an established pyruvate analogue (a structural isostere of 
pyruvic acid) described as a well characterised substrate-like competitive inhibitor of LDH. 
Promising anti-proliferative effects of oxamic acid have been reported in vitro in 
hepatocellular and breast carcinoma cell lines [33-36]. 
Several successful combinations of glycolytic inhibitors with cytotoxic drugs have recently 
been identified and glycolytic inhibitors have been demonstrated to resensitise drug-resistant 
cells to conventional regimens [12, 14, 15, 37-39].  
We have previously demonstrated antitumour activity of glycolytic inhibitors against panels 
of ovarian and breast cancer cell lines [40]. In the present study, we evaluated the levels of 
expression of four selected glycolytic targets (GLUT1, HKII, PKM2 and LDHA) in a large series 
of ovarian cancers to investigate possible associations with histological subtype and stage of 
disease. We have then used four inhibitors to target prime components of the pathway and 
compared these agents against paired chemosensitive and chemoresistant ovarian cancer cell 
lines. Novel combinations between cisplatin and paclitaxel with inhibitors of the glycolytic 
pathway were then investigated and evaluated quantitatively by comparison of their 
combination indices.  
 
Methods 
Study population 
Primary Ovarian cancer patients treated at the Edinburgh Cancer Centre between 1991-2006 
were retrospectively identified from the Edinburgh Ovarian Cancer Database. Tissues were 
formalin-fixed and paraffin-embedded. Haematoxylin-eosin stained slides were reviewed by 
a subspecialist gynaecological pathologist, and histological classification of tumour type 
confirmed. Three separate Tissue Microarray (TMA) replicates containing cores of 380 ovarian 
tumours were constructed. The number of samples available for histology and stage analysis 
is shown in Supplementary Table 1 and the full dataset used for analysis is given in Additional 
File 1. 
No informed consent was obtained for use of retrospective tissue samples from the patients 
within this study, most of whom were deceased, since this was not deemed necessary by the 
Ethics Committee. The TMA material was kindly provided by the Edinburgh Experimental 
Cancer Medicine Centre (ECMC ID: SR319). Ethical approval for the use of tumour material 
and correlation with associated clinical data was obtained from South East Scotland Human 
Annotated Bioresource (East of Scotland Research Ethics Service Reference 15/ES/0094). 
 
Immunofluorescence of clinical ovarian cancer tissues 
Microscope slides of TMA sections were deparaffinised and rehydrated followed by heat-
induced antigen retrieval being performed in sodium citrate buffer at pH6. Endogenous 
peroxidase activity was blocked with 3% hydrogen peroxide for 10min and non-specific 
binding was blocked by a 10min incubation in serum-free protein block (DAKO). Primary 
antibodies were diluted in antibody diluent (DAKO) and were applied overnight at 4ºC. The 
following primary rabbit antibodies, validated for the protocol, were used: GLUT1 (Merck 
Millipore), HKII (Cell Signaling Technology), LDHA (Cell Signaling Technology) and PKM2 (Cell 
Signaling Technology). The following day, tissue sections were washed with 0.05% PBS Tween 
20 (PBS-T), and were then incubated with primary mouse anti-cytokeratin antibody (M3515/ 
DAKO) diluted 1:25 in the same antibody diluent in order to mask the tumour areas. This 
incubation was performed at room temperature, lasted 1h and was followed by PBS-T 
washes. To enable epithelial mask visualisation, slides were then incubated with the 
secondary goat anti-mouse antibody conjugated with Alexa Fluor 555 (Thermo Fisher 
Scientific) diluted 1:25 in the goat anti-rabbit peroxidase-conjugated Envision reagent 
(DAKO). This incubation was conducted at room temperature protected from light for 90 min 
and was followed by PBS-T washes. Target visualisation was implemented by a 10min 
incubation with Cyanine 5 (Cy5) Tyramide, diluted at 1:50 in amplification diluent 
(PerkinElmer), at room temperature protected from light. Subsequently, tissue sections were 
washed with PBS-T and dehydrated. Finally, slides were counterstained with 45μl Prolong 
Gold Antifade Mountant with DAPI (4', 6-diamidino-2-phenylindole) (Thermo Fisher Scientific) 
to visualise the nuclei and a coverslip was mounted.  
 
 
 
AQUA Image Analysis 
Protein expression in the ovarian tumour cores was quantitatively evaluated by Automated 
Quantitative Analysis (AQUA) [41]. High resolution monochromatic images of each TMA core 
were captured at 20x objective using an Olympus AX-51 epifluorescence microscope and 
were analysed by AQUAnalysis software. DAPI, Cy-3 and Cy-5 filters were applied to visualise 
the nuclei, the cytokeratin tumour mask and the target protein respectively. The Cy-5 
fluorescent signal intensity of the target antigen was quantified in each image pixel. A 
quantitative score was attributed to each histospot based on the average Cy5 signal in the 
cytoplasmic compartment within the epithelial tumour mask, as identified by the cytokeratin 
Cy3 stain. Damaged cores or cores containing imaging errors as well as those consisting of 
less than 5% epithelium were excluded from further analysis. 
Target expression in the cytoplasmic compartment of each core was quantified and assigned 
an AQUA score. Data were filtered and only samples that had at least two replicate values 
were considered. Expression values were averaged from either two or three replicates. 
Spearman non-parametric correlation and network analysis were conducted using TMA 
Navigator [42]. Correlation heatmaps were generated using the same software 
(http://www.tmanavigator.org/). For this analysis, expression data of different markers had 
been log2 transformed, mean-centred and quantile-normalised to compensate for 
differences in the staining. The expression of examined glycolytic targets was compared 
across the different pathological stages and histological types of ovarian tumours using one-
way ANOVA and statistical significance was determined by the Tukey's multiple comparisons 
test. The Spearman correlation coefficient was calculated for each pair of markers and 
statistical significance was determined using the Algorithm AS89 [43]. Spearman's correlation 
P-values were adjusted for multiple hypothesis testing according to Benjamini-Yekutieli FDR 
correction. The P-value significance threshold was set at 0.01. 
 
Cell lines 
A panel of four ovarian cancer cell lines were used initially. OVCAR5, OVCAR3 and CAOV3 are 
HGSOC cell lines [44] while TOV112D is of endometrioid ovarian cancer origin [45]. OVCAR5 
and OVCAR3 were gifts from Dr Tom Hamilton, Fox Chase Institute, Philadelphia, PA USA while 
CAOV3 and TOV112D were obtained from American Type Culture Collection, Manassas, 
Virginia, USA. Two cell line pairs derived from two patients with HGSOC at different stages of 
platinum-based chemotherapy were also used – PEA1 / PEA2 and PE01/PE04 respectively 
[46]. The first cell line of each pair was regarded as chemosensitive and the second cell line 
(which was isolated following the development of platinum resistance), chemoresistant [46, 
47]. These were developed within our laboratory and are now available at the European 
Collection of Cell Cultures, Porton Down, UK. All cell lines used in this study were 
authenticated using Short Tandem Repeat profiling (STR) (by ECACC) and were routinely 
subjected to mycoplasma testing. 
 
 
Cell culture 
All cell line work was conducted in sterile conditions in a class II Laminar Air Flow hood at 
room temperature. Cells were incubated in a humidified atmosphere of 5% CO2 at 37oC.  The 
panel of four ovarian cancer cell lines (OVCAR5, TOV112D, OVCAR3 and CAOV3) were all 
maintained in Dulbecco's Modified Eagle Medium without HEPES modification (DMEM, 
Thermo Fisher Scientific), containing glucose (5.56mM), Sodium Pyruvate (1mM) and L-
glutamine (3.97mM). The two ovarian cancer cell line pairs (PEA1-PEA2, PEO1-PEO4) were 
maintained in RPMI 1640 (Thermo Fisher Scientific) containing 11.11mM glucose and 2mM L-
glutamine. In both cases the media contained phenol red and were supplemented with 10% 
heat inactivated fetal bovine serum FBS (Fetal Bovine Serum, Thermo Fisher Scientific) and 
1% Penicillin-Streptomycin (Penicillin-Streptomycin 10,000 U/mL, Thermo Fisher Scientific).  
In the deprivation experiments where the effect of glucose availability on cell growth of 
different cell lines was examined, medium without glucose was used (DMEM, Thermo Fisher 
Scientific). Phenol red free media were supplemented with 10% heat inactivated dialysed 
fetal bovine serum (Thermo Fisher Scientific) and 1% Penicillin-Streptomycin. In the glucose 
depleted medium the desired concentration of D-Glucose (Sigma Aldrich) was added along 
with a standard 4mM L-Glutamine (Sigma Aldrich) concentration. 
Cells were routinely maintained in T175cm3 tissue culture flasks and were sub-cultured at 
least once a week, when reaching 70-80% confluence as described below. Medium was 
discarded and cells were washed with preheated phosphate buffered saline. Cells were then 
incubated for a few minutes with a trypsin/EDTA solution (Trypsin-EDTA 0.05%,Thermo Fisher 
Scientific) to cause cell detachment and cell suspension was centrifuged at 1,200rpm for 
5min. Pelleted cells were resuspended in fresh media and transferred into new flasks. When 
setting up an experiment cells were counted using a Neubauer hemocytometer and were 
seeded in cell culture plates or dishes at the desired dilution. 
 
 
 
Sulphorhodamine B assay (SRB) 
The SRB assay is a colorimetric cell density assay based on the quantification of cellular 
protein content [48]. Cells were seeded in flat-bottom 96-well plates. After 48h incubation, 
cells were treated with or without the relevant treatment as indicated. STF31 and metformin 
were obtained from Tocris Bioscience, 3PO from Merck Millipore and oxamic acid from Sigma 
Aldrich. IOM-1190 was provided by IOmet Pharma. The compound  is example 187 in patent 
WO2014/187922 and has an imidazo pyrazine core [49].  
Cisplatin (Teva UK Limited) and paclitaxel (Actavis) were obtained as formulated drugs. Stock 
solutions of compounds were prepared in DMSO except for oxamic acid and metformin which 
were dissolved in PBS. A series of 10 dilutions with 1:2 steps of each inhibitor in six replicates 
was applied. Once the treatment period was completed, cell monolayers were fixed on the 
day of treatment (Day 0 control) and on selected time points thereafter with cold 25% 
trichloroacetic acid (TCA, Sigma Aldrich). Then cell monolayers were stained with 0.4% SRB 
dye solution (Sigma Aldrich) and unbound excess dye was removed by 1% glacial acetic acid 
(VWR International) washes. The protein bound stain was solubilised in 10mM Tris buffer 
solution pH 10.5 (Sigma Aldrich). Finally absorbance was measured at 540nm using a plate 
reader. 
Measurements were corrected for background absorbance and values are presented as 
percentage of absorbance of untreated control.  The half maximal inhibitory concentration 
(IC50), indicating the concentration needed to reduce cell viability by half, was used as a 
quantitative indication of the effectiveness of each compound as a cancer cell growth 
inhibitor. IC50 values were generated through sigmoidal concentration response curves fitted 
using the XL fit tool within Microsoft Excel. 
 
Combinatorial treatments 
In combination drug studies, glycolytic inhibitors were assessed in combination with 
traditional drugs. For these treatments a range of different concentrations of the glycolytic 
inhibitor were combined with a constant fixed concentration, around the IC20 or less, of the 
other drug. Both drugs were delivered at the same time and cancer cell proliferation was 
examined by the SRB assay after a 3-day treatment period. Concentration response curves of 
each examined combination along with curves of the two compounds as single agents were 
analysed using Calcusyn Software (Biosoft). To quantitatively evaluate the effectiveness of 
each combination, CI values were generated for each combination point indicating synergy, 
additivity or antagonism [50]. CI values lower than 0.8 indicate synergy, values between 0.8 
and 1.2 imply additivity while values higher than 1.2 indicate antagonism [50].  
 
Statistical Analysis 
Statistical tests were undertaken using GraphPad Prism software version 6. Student’s t-test 
was used to compare two groups and ANOVA followed by the Tukey post-test was used to 
compare more than two groups. For survival analysis, we undertook Kaplan Meier analysis 
using X-tile [51] which allows determination of the minimal p-value using the Miller-Siegmund 
minimal P correction. 
 
 
 
Results  
Expression of glycolytic enzymes in ovarian tumours and association with histological 
subtypes and stage 
To assess the variation in expression of key components of the glycolytic pathway in ovarian 
cancers, expression levels of GLUT1, HKII, PKM2 and LDHA were investigated in a series of 380 
ovarian tumours by Automated Quantitative Analysis (AQUA). A three label 
immunofluorescent protocol was used generating a quantitative score for each tumour core. 
Representative immunofluorescence images illustrating the expression of the four glycolytic 
targets in TMA cores of ovarian cancers are shown in Figure 1A-1D. GLUT1 showed membrane 
as well as cytoplasmic localisation while HKII, PKM2 and LDHA demonstrated cytoplasmic 
localisation (Figure 1A-1D). In Figure 1E, the expression of the four proteins is shown for an 
individual ovarian cancer case illustrating high expression for all four consistent with a 
glycolytic phenotype. 
Associations between the level of expression of the four molecules and the histological 
subtype of ovarian cancer were then examined (Figure 2). High-grade serous ovarian cancer 
(HGSOC) accounts for approximately 70% of epithelial ovarian cancers [2] and was first 
compared with non-HGSOC disease. Mean expression of GLUT1 was higher in HGSOC than in 
non-HGSOC samples (P=0.0011; t-test) (Figure 2A). Similarly, HKII expression was higher in 
HGSOC than non-HGSOC (P=0.031; t-test) and this was reflected in a difference between 
HGSOC and clear cell disease (P<0.05; Tukey test post ANOVA) (Figure 2B). In contrast, LDHA 
expression was lower in HGSOC than in non-HGSOC (P=0.022; t-test) and again this difference 
was reflected in HGSOC being lower than clear cell (P<0.01; Tukey test post ANOVA) (Figure 
2C). For PKM2, there were no statistically significant differences between the histological 
subtypes (Figure 2D). 
When stage of disease was analysed, GLUT1 expression was higher in advanced disease 
(stages III/IV) than early disease (stages I/II) (P=0.023; t-test) (Figure 3). In contrast, LDHA 
expression was lower in Stage IV than stage I disease (P<0.05; Tukey test post ANOVA) (Figure 
3) while no obvious differences emerged for HKII or PKM2. Analysis of the HGSOC group alone 
indicated no differences in expression between advanced and early stage HGSOC (data not 
shown). Analysis of patient survival using x-Tile optimal cut-point analysis [51] showed no 
significant differences in survival with varying  expression levels of the four molecules in any 
of the HGSOC, endometrioid or clear cell cancer groups (data not shown).   
A heatmap correlating the expression of the four examined glycolytic enzymes across the 
dataset is shown in Figure 4A. Spearman non-parametric correlation was performed and the 
correlation heatmap was generated using TMA Navigator [43]. The expression of the four 
targets across the ovarian cancers gave positive rho correlation values when compared to 
each other. Based on the dendrogram, LDHA expression appeared more closely correlated 
with PKM2 expression; in contrast HKII expression was more distant to the expression of the 
other three markers. Spearman correlation network analysis was conducted to further 
interpret the relationship between the glycolytic markers and evaluate their associations. The 
correlation network of expression of the four glycolytic enzymes is presented in Figure 4B. 
Significant relationships (FDR P<0.01) are drawn as lines that connect pairs of markers. 
Thickness of connection lines reflects significance and positive significant relationships are 
displayed in grey colour. The colour of each marker indicates the number of significant 
connections. High number of significant connections is displayed in yellow colour while low 
in blue. The correlation values (FDR P<0.01) are summarised in Supplementary Table 2.   
 
The effect of glucose on cell growth of a panel of ovarian cancer cell lines 
To assess the growth dependence of ovarian cancer cells on glucose, the proliferation of a 
small panel of ovarian cancer cell lines was monitored under a range of glucose 
concentrations after a 5-day incubation period. Growth was compared with controls in 
medium without glucose. Figure 5 illustrates the average optical density value generated via 
SRB assay (indicative of cell number) against increasing concentration of glucose. OVCAR5, 
CAOV3 and OVCAR3 are of HGSOC origin [45] while TOV112D is of endometrioid cancer origin 
[46]. OVCAR5 and CAOV3 cells were unable to proliferate when cultured in the absence of 
glucose for five days; 0.2mM of glucose was required for significant growth of OVCAR5 cells 
with higher concentrations leading to higher growth rate until a plateau was reached at 
1.6mM glucose. CAOV3 cells demonstrated significant growth, in comparison to the control 
samples, when cultured in a minimum of 0.4mM glucose. In contrast, OVCAR3 and TOV211D 
cells showed a threefold increase in their cell number in the absence of glucose however were 
still able to grow more rapidly in the presence of added glucose (Figure 5). 
 
The effect of glycolytic inhibitors on cell growth of chemosensitive and chemoresistant 
HGSOC ovarian cancer cell lines 
PEA1 / PEA2 and PEO1 / PEO4 are two pairs of cancer cell lines established from two individual 
patients with HGSOC [47]. The first cell line of each pair is platinum sensitive (PEA1 and PE01 
respectively) while the second line (PEA2 and PE04 respectively) was acquired after platinum 
resistance had developed within the patient [47, 48]. Four glycolytic inhibitors (IOM-1190, 
STF31, 3PO and oxamic acid) were investigated against these ovarian cancer cell line pairs 
(Figure 6) and IC50 concentrations are listed in Table 1.  These inhibitors were selected based 
on interest in targeting GLUT1 at the top and LDHA at the bottom of the pathway and also on 
preliminary evidence that the PFKFB3 inhibitor, 3PO, had interesting combinatorial activity in 
pilot experiments. 
IOM-1190 is a novel specific GLUT1 inhibitor [22] and attenuated cell proliferation of both 
chemosensitive and chemoresistant cell lines. PEA1 had an IC50 value equal to 280nM and 
PEA2 equal to 460nM. In contrast, the PEO4 platinum-resistant cell line presented greater 
sensitivity having a threefold lower IC50 value (equal to 1.6μΜ) compared to the platinum 
sensitive PEO1 cell line (4.8 μΜ). STF31, another GLUT1 inhibitor [21] had similar inhibitory 
activity against both cell lines of each pair. Although also reported as an NAMPT inhibitor [52], 
it reassuringly had a pattern of activity similar to that of IOM-1190. The PEA2 cell line was 
slightly more resistant to STF31 compared to its paired platinum naïve line PEA1, with IC50 
values of 1.3μΜ and 0.9μΜ respectively. In contrast, the platinum-resistant line PEO4, having 
an IC50 value of 0.9μΜ, showed increased sensitivity to the inhibitor compared to its paired 
platinum-sensitive line PEO1, with an IC50 value of 1.5μΜ. 3PO is a recently identified PFKFB3 
inhibitor [27]. Sensitivity to 3PO coincided with platinum sensitivity. Both platinum resistant 
cell lines (PEA2 and PE04) presented greater resistance to 3PO compared to their platinum 
sensitive paired cell lines with twofold higher IC50 value. Oxamic acid is an established LDH 
inhibitor [34-37]. The first ovarian cancer cell line pair responded similarly to this agent with 
an almost identical IC50 value of 16mM. Regarding the second pair, the PEO4 platinum 
resistant cell line proved to be more resistant to oxamic acid, having an IC50 value threefold 
higher than the corresponding value of PEO1 (Table 1).  These results indicate that, in general, 
platinum-resistant disease has comparable sensitivity to these glycolysis inhibitors when 
compared to chemo-sensitive disease. 
The PFKFB3 inhibitor, 3PO, potentiated the antiproliferative effect of cisplatin and 
paclitaxel in ovarian cancer cells 
Combinations of the PFKFB3 inhibitor, 3PO, with cisplatin and paclitaxel were next 
investigated against the paired cell lines. 3PO was able to enhance the effect of cisplatin in 
both the chemosensitive PEA1 and chemoresistant PEA2 cell lines. A range of different 
concentrations of 3PO were used in combination with a constant fixed concentration (around 
the IC20), of the cytotoxic drug; hence in PEA2 cells, 4μΜ of cisplatin was required to produce 
a similar inhibitory effect in cell number to that of 1μΜ cisplatin on PEA1 cells.   Both drugs 
were delivered at the same time and cancer cell proliferation was examined by the SRB assay 
after a 3-day treatment period. Combination Index values (CI) were generated for each 
combination point, using Calcusyn software, providing a quantitative evaluation of the 
combination efficacy. Concentrations at which synergistic interactions (CI values lower than 
0.8) between the two compounds were identified are indicated by asterisks in Figure 7A. The 
combination of 3PO with paclitaxel was also effective in inhibiting growth of the PEA1 and 
PEA2 cell lines, generating low CI values for all 3PO concentrations used (Figure 7.B). These 
drug combinations were similarly effective for the other examined ovarian cancer cell line 
pair PEO1 and PEO4 and also demonstrated synergistic activity (Supplementary Figure 1).  
 
Metformin potentiated the antiproliferative effect of glycolytic inhibitors on ovarian cancer 
cells 
We have previously reported promising combinatorial activity between metformin and STF31 
or oxamic acid in a breast cancer cell line [40]. Metformin inhibits the mitochondrial 
respiratory chain complex I and combination with a glycolytic inhibitor will result in more 
complete depletion of cellular ATP. The effect of either STF31 or oxamic acid on both 
chemosensitive and chemoresistant ovarian cancer cell lines was markedly enhanced by 
metformin (Figure 7.C). Strong synergy at the level of a CI value equal to 0.1 was 
demonstrated for both cell lines. These drug interactions were similarly effective for the other 
examined ovarian cancer cell line pair (PEO1-PEO4, Supplementary Figure 1C). 
 
Discussion  
There is continued interest in the potential of targeting the glycolytic pathway as a 
therapeutic strategy for cancer treatment [15, 17, 45, 46]. In this study we evaluated the 
relative expression of several glycolytic markers across a large cohort of clinical ovarian 
tumours by use of in situ immunofluorescence staining. We are not aware of any previous 
study which has reported the expression of multiple glycolytic enzymes in ovarian tumours 
and certainly none that include a cohort of this size. 
Analysis of histological subtype indicated higher expression of GLUT1 in HGSOC, the most 
frequently occurring form of epithelial ovarian cancer. Previous studies in small series of 
tumours have demonstrated increasing GLUT1 expression when comparing ovarian benign 
and borderline tumours to malignant ovarian adenocarcinomas and this transporter has been 
suggested as a potential marker of ovarian malignancy [53, 54, 55]. Our data is in line with a 
number of studies which have documented elevated GLUT1 expression in serous 
adenocarcinomas [54, 56-58]. Significantly higher GLUT1 expression was detected in 
advanced stage (III/IV) tumours compared to early stage (I/II) cancers. This is consistent with 
a previous report of increased GLUT1 expression being higher in advanced stage ovarian 
tumours [56]. GLUT1 has been proposed as a marker of adverse prognosis in ovarian cancer, 
however we did not observe an effect on survival in this cohort of patients [58]. Cantuaria et 
al associated GLUT1 overexpression with poor disease free survival rate in 89 advanced stage 
ovarian carcinomas [59] while Semaan et al demonstrated that high GLUT1 expression had a 
negative impact on the overall survival of 213 ovarian cancer patients [57]. Consistent with 
these reports, Cho et al described a reverse statistically significant association among overall 
survival of 50 patients and high GLUT1 expression [58]. Enhanced tracer [F-18]-
fluorodeoxyglucose (FDG) uptake, quantified by PET, has been shown to relate to increased 
GLUT1 expression in ovarian cancer and was related to increased cellular proliferation [60]. 
As for GLUT1, we observed that HKII was increased in HGSOC relative to non-HGSOC. The 
mitochondrial-bound HKII is the predominant isoform expressed in many tumours. Increased 
HKII expression has been noted in ovarian cancer for malignant tumours compared to benign 
and borderline tumours and increased HKII expression in serous carcinomas was found 
compared to non-serous tumours [61].  Suh et al examined HKII expression by IHC in 111 
ovarian tumours and documented that high HKII was correlated with chemoresistance and 
disease recurrence as well as decreased progression free survival [62].  
The dependence of ovarian cancer cell growth on glucose was next assessed by investigating 
the effect of varying glucose concentration in culture. The mean physiological level of glucose 
in the plasma is approximately 5mM, with a maximum concentration of 9mM after eating and 
a minimum of 3mM following physical exercise or moderate fasting [63]. Frequently the 
concentration of glucose in malignant tissues is significantly lower (up to 10 fold) than their 
normal counterparts in consequence of augmented glucose consumption and abnormal 
tumour microvasculature [64]. The ovarian cancer cell lines demonstrated differential ability 
to grow in the absence of glucose. TOV112D and OVCAR3 were both able to increase their 
cell number up to threefold in glucose depleted conditions while in contrast OVCAR5 and 
CAOV3 were unable to grow when glucose was not present in the culture medium (Figure 5). 
For CAOV3 cells, a relatively high concentration equal to 0.4mM was required for significant 
growth. Interestingly OVCAR5, TOV112D and CAOV3 cells reached a plateau of maximal 
growth at 1.6mM glucose. In contrast, OVCAR3 cells demonstrated optimal growth when 
cultured in a low glucose environment of 0.4mM.  Glucose deprivation has been extensively 
associated with oxidative stress [65, 66]. Aykin-Burns et al attributed the increased sensitivity 
of breast cancer cells to glucose withdrawal (and subsequently to glucose inhibition) 
compared to normal mammary epithelial cells, to the pro-oxidant status mediated by 
elevated ROS production [66]. In line with these findings Graham et al also confirmed the 
association between the metabolic reconfiguration of tumours and increased sensitivity to 
glucose deprivation. They linked glucose depletion with elevated tyrosine kinase signalling 
and ROS mediated cell death [67].   
In a previous report, we provided evidence that nine compounds targeting key components 
of the glycolytic pathway inhibited cancer cell proliferation in a concentration-dependent 
manner [40]. To explore this further, the effects of several inhibitors targeting key enzymes 
of the glycolytic pathway were investigated against paired chemosensitive/chemoresistant 
HGSOC cell line models. Recent evidence has associated drug resistance with an elevated 
dependency on the glycolytic phenotype however much less is known as to whether glycolysis 
inhibition could be exploited against resistant disease [68]. Targeting three major 
components of glycolysis proved effective in attenuating ovarian cancer cell proliferation in a 
concentration-dependent manner regardless of platinum sensitivity. The recently developed 
agents, IOM-1190, STF31 and 3PO were considerably more potent in inhibiting cancer cell 
proliferation compared to the more established oxamic acid that required concentrations in 
the millimolar concentration range (Table 1).  
Currently, the administration of antitumour therapy generally involves combinatorial 
strategies of several therapeutic agents. Drug combinations aim to augment the therapeutic 
benefit, reduce the adverse effects and delay or ideally hinder resistance. Resistance to 
common chemotherapeutic agents has been associated with the deregulated reliance of 
tumours on the glycolytic pathway. It has been suggested that targeting the metabolic 
phenotype of tumours may enhance the efficacy of chemotherapy regimens and moreover 
resensitise tumour cells to treatment to which they had developed resistance [39, 40]. 
Possible proposed mechanisms predict glycolysis inhibition reducing cellular ATP levels and 
compromising the activation of resistance pathways or attenuating tumour growth promoting 
induction of apoptosis and hindering the adaptation to chemotherapeutic treatment [39, 40]. 
Platinum-based drugs  are the most widely used agents for the treatment of ovarian cancer 
however platinum-refractory disease frequently develops and hence combinatorial 
treatments with other antitumour agents are currently under investigation, aiming to 
alleviate adverse effects and overcome resistance [69]. We observed that the PFKFB3 
inhibitor 3PO significantly enhanced the cytotoxic effect of cisplatin against both platinum 
sensitive and platinum resistant ovarian cancer cells. This supports the view that 
combinatorial treatment of cisplatin with 3PO could reverse the platinum resistant phenotype 
and may be an effective strategy against platinum-resistant ovarian tumours. It should be 
noted that the concentrations of the two drugs that gave the lowest CI values are relatively 
low and potentially achievable in in vivo experiments. Paclitaxel (given 3-weekly) along with 
carboplatin is the other first line treatment for ovarian cancer. In addition, paclitaxel is also 
often used in a weekly schedule in platinum resistant disease. 3PO combined with paclitaxel 
produced synergistic anticancer action on ovarian cancer cells. Both PEA1 and PEA2 cell lines 
were very sensitive to this combination and the effectiveness of this combination especially 
for the resistant PEA2 line suggests that this combination might have in vivo potential.  
To date a number of studies have revealed that certain compounds targeting the glycolytic 
metabolism of tumours might improve the therapeutic index of chemotherapeutic cytotoxic 
agents mainly through reduction of the ATP levels selectively in malignant cells [39, 40]. 
Similar to this study’s observations Liu et al reported synergistic antitumour action between 
the GLUT1 inhibitor WZB117 and cisplatin or paclitaxel [70]. Another glucose transport 
inhibitor, the phytochemical Phloretin, has been shown to potentiate the cytotoxic effect of 
daunorubicin promoting apoptosis and also sensitised resistant leukaemia and colon cancer 
cells to the anthracycline exclusively under hypoxic conditions [71]. Nakano et al documented 
that the HKII inhibitor 3BP enhanced the anticancer effects of daunorubicin and doxorubicin 
in leukaemia and myeloma cells both in vitro and in vivo. The glycolytic inhibitor diminished 
the cellular ATP levels which led to inactivation of the ATP-binding cassette transporters (ABC) 
therefore preventing the agent’s efflux from malignant cells [72].  
Metformin is a biguanide widely used for the treatment of type 2 diabetes mellitus. The drug 
reduces insulin resistance and blood glucose levels through inhibition of mitochondrial 
respiratory chain complex 1 leading to reduced ATP production and subsequently provoking 
AMPK activation and mTOR inhibition [73, 74]. A considerable number of epidemiologic meta-
analyses have associated metformin with a decreased incidence of several malignancies as 
well as with improved clinical outcome and reduced cancer-related mortality of diabetic 
cancer patients. Anti-proliferative action has been extensively demonstrated in preclinical 
studies in several types of cancer [72-77] and metformin is an attractive candidate for 
combinatorial cancer treatment. Experimentally, metformin enhanced the cytotoxic effect of 
several agents including cisplatin, paclitaxel and doxorubicin [73, 79, 80]. Metformin is 
currently being assessed in numerous clinical trials in various cancer types as 
chemoprevention, monotherapy or in combination with several chemotherapeutic agents 
[73-78]. However, to date little attention has been paid to a possible interaction among 
glycolytic inhibitors and the antidiabetic drug. We previously reported a beneficial interaction 
between the glycolytic inhibitors STF31 and oxamic acid when combined with metformin in a 
triple negative breast cancer cell line model [40]. In the present study, we observed that 
metformin augmented STF31 and oxamic acid-induced cytotoxicity in both platinum sensitive 
and platinum resistant ovarian cancer cells. It was observed that while low concentrations of 
the antidiabetic drug and the glycolytic inhibitors had only marginal effects on the growth of 
ovarian cancer cell lines, in combination they induced a marked antitumour effect 
characterised by low synergistic CI values. This data extends our previous findings obtained 
in a breast cancer model [40] and provides further evidence that suggests that dual inhibition 
of the two energy pathways might be a promising antitumour therapeutic strategy for 
ovarian, as well as breast, cancer. Further research should now be undertaken to validate 
these promising in vitro pilot data and investigate their in vivo therapeutic potential.  
 
Conclusions 
To the best of our knowledge this is the first study evaluating the expression of a series of 
glycolytic enzymes in a large cohort of ovarian tumours. We observed that HGSOC and 
advanced stage tumours frequently express higher levels of GLUT1 and HKII, the initial 
components of the pathway. Cell lines from HGSOC that are resistant to cytotoxic treatment 
retain comparable sensitivity to glycolytic inhibitors. Combination of glycolytic inhibitors with 
chemotherapy can produce significantly increased growth inhibition. This study supports 
further consideration of the use of glycolytic inhibitors for the treatment of ovarian cancer.  
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Table 1. IC50 concentrations for glycolysis inhibitors against the PEA1/PEA2 and PE01/PE04 
pairs of HGSOC cell lines. 
IC50 values 
1st pair 2nd pair 
PEA1 PEA2 PEO1 PEO4 
IOM-1190 (μM) 0.28 0.46 4.8 1.6 
STF31 (μM) 0.86 1.3 1.5 0.88 
3PO (μM) 6.3 11.9 3 6.8 
Oxamic acid (mM) 16 17.6 3.8 10.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legends 
Figure 1. A-D. Representative immunofluorescence images showing GLUT1, HKII, PKM2 and 
LDHA expression in TMA cores of ovarian cancers. E. Immunofluorescence images showing 
expression of four glycolytic enzymes in TMA cores of an individual ovarian cancer patient. 
Blue colour visualises DAPI nuclear counterstain, green colour cytokeratin tumour mask and 
red colour target staining. Quantified target expression (AQUA value) in the cytoplasmic 
compartment of each core is indicated.  
Figure 2. Expression levels of four glycolytic enzymes in different histological subtypes of 
ovarian cancer. AQUA levels of GLUT1, HKII, PKM2 and LDHA are shown. Values were 
measured as described in Methods section. The boxplot shows the median value, with the 
rectangle representing the 2nd and 3rd quartiles. Statistical significance indicated (Student’s t-
test).   
Figure 3. Expression levels of four glycolytic enzymes in different stages of ovarian cancer. 
AQUA levels of GLUT1, HKII, PKM2 and LDHA are shown. Values were measured as described 
in Methods section. The boxplot shows the median value, with the rectangle representing the 
2nd and 3rd quartiles.  
 
Figure 4.  Heatmap and correlation network analysis of the expression of four glycolytic 
enzymes in a cohort of 380 ovarian cancers. A. Heatmap showing the positive Spearman rho 
correlation values displayed in bright yellow colours and the negative Spearman rho 
correlation values in dark blue colours. The heatmap was generated using TMA Navigator 
[42]. B: Spearman correlation network of the four glycolytic enzymes in the cohort. 
Statistically significant correlations thresholded at FDR P<0.01 are presented. High number of 
significant connections is displayed in bright yellow colours while low in dark blue colours. 
Positive relationships are indicated in grey while negative in red. Thickness of connection lines 
reflects significance (the adjusted P value). The network was generated using TMA Navigator 
[42]. 
 
Figure 5: Growth response of a panel of four ovarian cancer cell lines in the presence of 
varying concentrations of glucose. Glucose concentrations between 0 and 25.6mΜ were 
evaluated and cells grown for a 5-day period. Optical density was determined by an SRB assay. 
Mean results of 6 replicates are reported and error bars represent standard deviations. Faint 
coloration at the bottom of the columns represents OD value on the day of treatment (Day 
0). Statistical significance indications: ns not significant P>0.05, * P<0.05, ** P<0.01, *** 
P<0.001 compared with the mean of the depleted controls (one-way ANOVA followed by 
Tukey-Kramer multiple comparisons test). 
 
Figure 6: Growth response curves of ovarian cancer cell line pairs treated with glycolysis 
inhibitors. IOM-1190 was used at concentrations between 0.2-100μΜ, STF31 and 3PO at 
concentrations between 0.06-30μΜ and oxamic acid at concentrations between 0.4-100mΜ 
for a 4-day period. Cell viability was determined by an SRB assay. Mean results of 6 replicates 
are reported and error bars represent standard deviations. Values are shown as a percentage 
of control. A constant 1% DMSO concentration was used across the whole curve for IOM-1190 
and a respective constant 0.3% DMSO concentration for STF31 and 3PO.  IC50 concentrations 
are listed in Table 1. 
 
Figure 7: Growth response curves of PEA1 and PEA2 ovarian cancer cells treated with 
combinations of glycolysis inhibitors with chemotherapy or metformin. A. 3PO with cisplatin. 
3PO concentrations between 0.5-30μΜ alone (blue line) or combined with a constant 
concentration of cisplatin (red line) were evaluated. In green the effect of 1μΜ (PEA1) or 4μΜ 
(PEA2) cisplatin on cell viability is presented.  B. 3PO with paclitaxel. 3PO concentrations 
between 0.5-30μΜ alone (blue line) or combined with a constant concentration of paclitaxel 
(red line) were evaluated. In green the effect of 1μΜ (PEA1) or 2μΜ (PEA2) paclitaxel on cell 
viability is presented. C. STF31 with metformin. Concentration response curves of PEA1 and 
PEA2 ovarian cancer cells treated with STF31 concentrations between 0.5-30μΜ alone (blue 
line) or combined with 1mM metformin (red line). In green the effect of 1mM metformin on 
cell viability is presented. D. Oxamic acid with metformin. Concentration response curves of 
PEA1 and PEA2 ovarian cancer cells treated with oxamic acid concentrations between 1.56-
100mΜ alone (blue line) or combined with 1mM metformin (red line). In green the effect of 
1mM metformin on cell viability is presented. Cell viability was determined by an SRB assay 
after a 3-day treatment. Mean results of 6 replicates are reported and error bars represent 
standard deviations. Values are shown as a percentage of control. Asterisks indicate 
synergistic combination points with *CI value lower than 0.8 and **CI value lower than 0.3.  
 
 
 
 
 
 
Supplementary Figure 1: Growth response curves of PE01 and PE04 ovarian cancer cells 
treated with combinations of glycolysis inhibitors with chemotherapy or metformin. A. 3PO 
with cisplatin. 3PO concentrations between 0.5-30μΜ alone (blue line) or combined with a 
constant concentration of cisplatin (red line) were evaluated. In green the effect of 0.5μΜ 
(PE01) or 1μΜ (PE04) cisplatin on cell viability is presented.  B. 3PO with paclitaxel. 3PO 
concentrations between 0.5-30μΜ alone (blue line) or combined with a constant 
concentration of paclitaxel (red line) were evaluated. In green the effect of 2μΜ paclitaxel 
(both PE01 and PE04) on cell viability is presented. C. Oxamic acid with metformin. 
Concentration response curves of PE01 and PE04 ovarian cancer cells treated with oxamic 
acid concentrations between 1.56-100mΜ alone (blue line) or combined with 2mM (PE01) or 
0.5mM (PE04) metformin (red line). In green the effect of 2mM (PE01) or 0.5mM (PE04) mM 
metformin on cell viability is presented. Cell viability was determined by an SRB assay after a 
3-day treatment. Mean results of 6 replicates are reported and error bars represent standard 
deviations. Values are shown as a percentage of control. Asterisks indicate synergistic 
combination points with * CI value lower than 0.8 and ** CI value lower than 0.3. 
 Additional File 1.  TMA dataset.  Mean AQUA expression values for GLUT1, LDHA, HKII and 
PKM2 in 380 ovarian cancer samples. Histology and stage are shown for individual tumours. 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
  
  
 
 
 
 
  
Supplementary Table 1: Number of ovarian cancer samples analysed by histology and stage. 
Histology 
HGSOC Endometrioid Clear cell Mucinous LGSOC 
 282 55 25 10 8 
Stage I II III IV 
Unknown 
39 43 219 66 13 
 
HGSOC refers to high grade serous ovarian cancer, while LGSOC refers to low grade serous 
ovarian cancer. 
 
 
Supplementary Table 2: Spearman correlation of the expression of four glycolytic enzymes in 
a cohort of 380 ovarian cancers. Spearman rho correlation values (top value) along with the 
respective adjusted P value (bottom value) of statistically significant correlations thresholded 
at FDR P<0.01 are summarised. 
Nonparametric  
Correlation 
GLUT1 HKII PKM2 LDHA 
GLUT1 * 0.202 0.007 
0.269 
0.0002 
0.234 
0.002 
HKII 0.202 0.007 * 
0.340 
0.000002 - 
PKM2 0.269 0.0002 
0.340 
0.0000025 * 
0.456 
5.02e-12 
LDHA 0.234 0.002 - 
0.456 
5.02e-12 * 
 
 
 
 
